4.6 Article

RIG-I activation induces the release of extracellular vesicles with antitumor activity

期刊

ONCOIMMUNOLOGY
卷 5, 期 10, 页码 -

出版社

TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2016.1219827

关键词

BAG6; exosomes; extracellular vesicles; melanoma; NK cells; NKp30; RIG-I

资金

  1. Deutsche Forschungsgemeinschaft [KFO286, SFB832, SFB670, SFB704, KFO177]
  2. BONFOR grants of the University Hospital Bonn
  3. DFG

向作者/读者索取更多资源

Activation of the innate immune receptor retinoic acid-inducible gene I (RIG-I) by its specific ligand 5-triphosphate-RNA (3pRNA) triggers antitumor immunity predominantly via NK cell activation and direct apoptosis induction in tumor cells. However, how NK cells are mobilized to attack the tumor cells remains elusive. Here, we show that RIG-I activation induced the secretion of extracellular vesicles (EVs) from melanoma cells, which by themselves revealed antitumor activity in vitro and in vivo. RIG-I-induced EVs from melanoma cells exhibited an increased expression of the NKp30-ligand (BAG6, BAT3) on their surface triggering NK cell-mediated lysis of melanoma cells via activation of the cytotoxicity NK cell-receptor NKp30. Moreover, systemic administration of RIG-I-induced melanoma-EVs showed a potent antitumor activity in a melanoma mouse model in vivo. In conclusion, our data establish a new RIG-I-dependent pathway leading to NK cell-mediated tumor cell killing.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Hematology

Allogeneic stem cell transplant recipients admitted to the intensive care unit during the peri-transplant period have unfavorable outcomes-results of a retrospective analysis from a German university hospital

Jorge Garcia Borrega, Jan-Michel Heger, Philipp Koehler, Udo Holtick, Michael Hallek, Christof Scheid, Boris Boell, Alexander Shimabukuro-Vornhagen, Matthias Kochanek, Dennis A. Eichenauer

Summary: Improvements in prognosis have been observed for allogeneic stem cell transplant recipients admitted to the ICU over the last few decades. However, patients requiring mechanical ventilation, renal replacement therapy, or vasopressors during their ICU stay showed decreased survival rates. Characteristics at baseline did not impact outcomes, and none of the patients who underwent CPR were alive at one year post-ICU discharge.

ANNALS OF HEMATOLOGY (2022)

Article Hematology

The CLL12 trial: ibrutinib vs placebo in treatment-naive, early-stage chronic lymphocytic leukemia

Petra Langerbeins, Can Zhang, Sandra Robrecht, Paula Cramer, Moritz Fuerstenau, Othman Al-Sawaf, Julia von Tresckow, Anna-Maria Fink, Karl-Anton Kreuzer, Ursula Vehling-Kaiser, Eugen Tausch, Lothar Mueller, Michael Josef Eckart, Rudolf Schlag, Werner Freier, Tobias Gaska, Christina Balser, Marcel Reiser, Martina Stauch, Clemens-Martin Wendtner, Kirsten Fischer, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek

Summary: Observation is the standard of care for early-stage asymptomatic chronic lymphocytic leukemia (CLL) patients, as chemotherapy-based interventions have not been effective in prolonging survival. However, early intervention with ibrutinib may lead to superior disease control and is well tolerated. The CLL12 trial showed that ibrutinib significantly improved event-free survival in asymptomatic, treatment-naive early-stage CLL patients at increased risk of progression, without increasing overall toxicity.
Editorial Material Medicine, General & Internal

Antibody Therapy in Patients with COVID-19

M. Augustin, M. Hallek, S. Nitschmann

INTERNIST (2022)

Editorial Material Medicine, General & Internal

Risk of myocarditis associated with mRNA vaccines for prevention of COVID-19

M. Augustin, M. Hallek, S. Nitschmann

INTERNIST (2022)

Article Oncology

A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression

Theophilos Tzaridis, Johannes Weller, Daniel Bachurski, Farhad Shakeri, Christina Schaub, Peter Hau, Andreas Buness, Uwe Schlegel, Joachim-Peter Steinbach, Clemens Seidel, Roland Goldbrunner, Niklas Schaefer, Robert J. Wechsler-Reya, Michael Hallek, Bjoern Scheffler, Martin Glas, Lothar Haeberle, Ulrich Herrlinger, Christoph Coch, Katrin S. Reiners, Gunther Hartmann

Summary: Evaluation of serum-derived extracellular vesicles (EVs) from glioblastoma patients reveals that the upregulation of CD29, CD44, CD81, C1QA, and histone H3 in serum EVs correlates with tumor progression, suggesting their potential as biomarkers.

INTERNATIONAL JOURNAL OF CANCER (2023)

Article Oncology

Cancer care in German centers of excellence during the first 2 years of the COVID-19 pandemic

Volker Arndt, Daniela Doege, Stefan Froehling, Peter Albers, Hana Alguel, Ralf Bargou, Carsten Bokemeyer, Martin Bornhaeuser, Christian H. Brandts, Peter Brossart, Sara Yvonne Brucker, Tim H. Bruemmendorf, Hartmut Doehner, Norbert Gattermann, Michael Hallek, Volker Heinemann, Ulrich Keilholz, Thomas Kindler, Cornelia von Levetzow, Florian Lordick, Ulf Peter Neumann, Christoph Peters, Dirk Schadendorf, Stephan Stilgenbauer, Thomas Zander, Daniel Zips, Delia Braun, Thomas Seufferlein, Gerd Nettekoven, Michael Baumann

Summary: The capacities of German Comprehensive Cancer Centers (CCCs) in various aspects of oncology care were significantly affected during the first 2 years of the COVID-19 pandemic. Follow-up, psycho-oncologic care, and tumor surgery were particularly impacted, along with other areas of multidisciplinary oncological care. This study highlights the importance of developing strategies to prevent similar limitations in the future.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2023)

Article Oncology

Tripartite antigen-agnostic combination immunotherapy cures established poorly immunogenic tumors

Sven Borchmann, Carolin Selenz, Mia Lohmann, Hanna Ludwig, Asmae Gassa, Johannes Braegelmann, Philipp Lohneis, Lydia Meder, Julia Mattlener, Sara Breid, Marieke Nill, Jana Fassunke, Amy J. Wisdom, Anik Compes, Birgit Gathof, Hakan Alakus, David Kirsch, Khosro Hekmat, Reinhard Buettner, H. Christian Reinhardt, Michael Hallek, Roland T. Ullrich

Summary: The research shows that the novel combination immunotherapy named TRI-IT can effectively enhance the efficacy of immunotherapy in poorly immunogenic tumors by coactivating various antitumor immune responses without inducing off-target toxicity.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Article Oncology

CD20 Expression as a Possible Novel Prognostic Marker in CLL: Application of EuroFlow Standardization Technique and Normalization Procedures in Flow Cytometric Expression Analysis

Anke Schilhabel, Peter Jonas Walter, Paula Cramer, Julia von Tresckow, Saskia Kohlscheen, Monika Szczepanowski, Anna Laqua, Kirsten Fischer, Barbara Eichhorst, Sebastian Boettcher, Christof Schneider, Eugen Tausch, Monika Brueggemann, Michael Kneba, Michael Hallek, Matthias Ritgen

Summary: This study investigated the impact of CD20 expression on the response to anti-CD20 therapy in chronic lymphocytic leukemia patients. A bead-based normalization approach was used to analyze CD20 expression levels, and it was found that high pre-therapeutic CD20 expression correlated with a profound response to Ofatumumab.

CANCERS (2022)

Article Hematology

Characteristics and outcomes of patients undergoing high-dose chemotherapy and autologous stem cell transplantation admitted to the intensive care unit: a single-center retrospective analysis

Jorge Garcia Borrega, Boris Boell, Matthias Kochanek, Jan-Hendrik Naendrup, Florian Simon, Noelle Sieg, Michael Hallek, Peter Borchmann, Udo Holtick, Alexander Shimabukuro-Vornhagen, Dennis A. Eichenauer, Jan-Michel Heger

Summary: A retrospective analysis was conducted on patients admitted to the intensive care unit (ICU) during hospitalization for high-dose chemotherapy and autologous stem cell transplantation (ASCT). The study found that the overall outcome was favorable for these patients.

ANNALS OF HEMATOLOGY (2023)

Article Oncology

Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients

Nadine Kutsch, Emily Eva Holmes, Sandra Robrecht, Gudrun Schueler, Ursula Vehling-Kaiser, Thomas Decker, Sigrun Mueller-Hagen, Karin Heinisch, Sebastian Boettcher, Matthias Ritgen, Karl-Anton Kreuzer, Stephan Stilgenbauer, Anna Maria Fink, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Clemens-Martin Wendtner

LEUKEMIA & LYMPHOMA (2023)

Article Cell Biology

Assessment of technical and clinical utility of a bead-based flow cytometry platform for multiparametric phenotyping of CNS-derived extracellular vesicles

Alexandra Brahmer, Carsten Geiss, Andriani Lygeraki, Elmo Neuberger, Theophilos Tzaridis, Tinh Thi Nguyen, Felix Luessi, Anne Regnier-Vigouroux, Gunther Hartmann, Perikles Simon, Kristina Endres, Stefan Bittner, Katrin S. Reiners, Eva-Maria Kraemer-Albers

Summary: Extracellular vesicles (EVs) released by cells carry specific biomolecules that can be used as liquid-biopsy markers for diagnosing brain diseases. This study evaluated a flow cytometry platform called EV Neuro assay for identifying and characterizing CNS-derived EVs and disease-specific markers in complex samples. The study compared different sample materials and EV isolation methods and found distinct EV profiles in glioblastoma cell lines and human astrocytes. The intensity of EV markers increased with higher EV input. Analysis of blood samples from patients with brain diseases and healthy controls showed varying EV marker intensities between individuals. Data normalization improved the identification of disease-specific markers. The EV Neuro assay proved useful for profiling EVs in complex samples. However, larger sample cohorts and higher effect sizes are needed for more reliable results in biomarker studies. Nonetheless, this study confirmed the potential of the EV Neuro assay for discovering disease-associated EV markers and monitoring circulating EV profiles in CNS diseases.

CELL COMMUNICATION AND SIGNALING (2023)

Article Oncology

Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies

Ruth Fluemann, Julia Hansen, Benedikt W. Pelzer, Pascal Nieper, Tim Lohmann, Ilmars Kisis, Tobias Riet, Viktoria Kohlhas, Phuong-Hien Nguyen, Martin Peifer, Nima Abedpour, Graziella Bosco, Roman K. Thomas, Moritz Kochanek, Jacqueline Knufer, Lorenz Jonigkeit, Filippo Beleggia, Alessandra Holzem, Reinhard Buttner, Philipp Lohneis, Jorn Meinel, Monika Ortmann, Thorsten Persigehl, Michael Hallek, Dinis Pedro Calado, Markus Chmielewski, Sebastian Klein, Joachim R. Goethert, Bjoern Chapuy, Branko Zevnik, F. Thomas Wunderlich, Bastian von Tresckow, Ron D. Jachimowicz, Ari M. Melnick, Hans Christian Reinhardt, Gero Knittel

Summary: Genomic profiling identified 5 subtypes of DLBCL, including the MCD/C5 cluster with MYD88, BCL2, PRDM1, and/or SPIB aberrations. Mouse models with B cell-specific Prdm1 or Spib aberrations were generated, showing molecular features of prememory and light-zone B cells. Combined BTK/BCL2 inhibition exhibited therapeutic activity in both mouse models and relapsed/refractory DLBCL patients.

BLOOD CANCER DISCOVERY (2023)

Article Medicine, General & Internal

Recurrent SARS-CoV-2 infections in immunodeficiency

L. Tometten, J. J. Malin, E. Pracht, P. J. Broeckelmann, C. Horn, R. Sprute, C. A. Langhorst, M. Hallek, G. Faetkenheuer, J. Rybniker

Summary: Immunodeficient patients with chronic and recurrent SARS-CoV-2 infections pose a significant health threat and present a major challenge in terms of treatment during the ongoing pandemic. Limited therapeutic options and emerging virus variants with immune escape mechanisms further complicate the medical care of these patients.

INNERE MEDIZIN (2023)

Meeting Abstract Hematology

Noninvasive, Dynamic Risk Profiling of Primary Central Nervous System Lymphoma By Peripheral Blood Ctdna-Sequencing

Jan-Michel Heger, Julia Mattlener, Philipp Godel, Hyatt Balke-Want, Noelle Sieg, Nadine Kutsch, Kerstin Becker, Jonathan Weiss, H. Christian Reinhardt, Michael Hallek, Peter Borchmann, Bastian von Tresckow, Sven Borchmann

Article Hematology

Desiccating Stress Significantly Increases the Risk for Chronic Ocular Graft-versus-Host-Disease

Uta Gehlsen, Michael E. Stern, Jeremy Franklin, Volkan Tahmaz, Michael Hallek, Udo Holtick, Christof Scheid, Philipp Steven

Summary: Desiccating stress is identified as an independent risk factor for ocular graft-versus-host disease (oGVHD), and adjusting air humidity during transplantation has the potential to serve as a preventive measure.

TRANSPLANTATION AND CELLULAR THERAPY (2022)

暂无数据